Crossmark

Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis

Crossref DOI link: https://doi.org/10.1007/s10620-022-07704-4

Published Online: 2022-09-30

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Khakoo, Nidah Shabbir

Sultan, Shahnaz

Reynolds, John M.

Levy, Cynthia https://orcid.org/0000-0001-5498-6037
License Information

Text and Data Mining valid from 2022-09-30

Version of Record valid from 2022-09-30
More Information

Article History

Received: 5 January 2022

Accepted: 16 September 2022

First Online: 30 September 2022

Declarations

:

: NSK, SS, JR have no financial conflicts of interest to disclose. CL has research grants from CymaBay, Genfit, Intercept, Zydus, Cara Therapeutics, Mirum, Calliditas, Gilead, GSK and TARGET-RWE. CL has consulting fees from CymaBay, Genfit, Cara Therapeutics, Mirum, Calliditas and GSK.

Document is current

Any future updates will be listed below